Study Guide for PSY 364- Behavioral Neuroscience Final Exam Fall 2023

PSY 364 Study Guide – Fall 2024


behavioral neuroscience :

  1. How are proteins measured?

    • Techniques: Proteins are quantified using methods like Western blotting, ELISA, mass spectrometry, and immunohistochemistry.

    • Western Blotting: Separates proteins by size, then uses antibodies for detection.

    • ELISA: Detects and quantifies specific proteins using enzyme-linked antibodies.

    • Mass Spectrometry: Identifies proteins and their post-translational modifications with high precision.

  2. How are neurotransmitter concentrations measured?

    • Techniques:

      • High-Performance Liquid Chromatography (HPLC) coupled with electrochemical detection.

      • Microdialysis for real-time measurement in the brain.

      • Immunoassays and radioligand binding assays for sensitivity and specificity.

  3. Describe the main anatomical features of a neuron.

    • Soma (Cell Body): Contains the nucleus and organelles.

    • Dendrites: Branched extensions receiving synaptic inputs.

    • Axon: Long projection transmitting action potentials.

    • Axon Hillock: Site of action potential initiation.

    • Synaptic Terminals: Release neurotransmitters.

  4. Describe the distribution of Na+ and K+ ion concentrations in a neuron at rest.

    • Na+: Higher outside the cell (~145 mM extracellular; ~15 mM intracellular).

    • K+: Higher inside the cell (~140 mM intracellular; ~4 mM extracellular).

    • Maintained by the Na+/K+ pump, which exchanges 3 Na+ out for 2 K+ in.

  5. Electrochemical forces on ions at various potentials:

    • At -70 mV (resting potential):

      • Na+: Strong inward driving force due to both concentration and electrical gradients.

      • K+: Weak outward driving force due to a concentration gradient opposing the electrical gradient.

    • At +45 mV (peak of action potential):

      • Na+: Minimal driving force; equilibrium potential (~+60 mV).

      • K+: Strong outward driving force due to concentration and electrical gradients aligning.


Action Potential and Synaptic Transmission

  1. Describe saltatory conduction.

    • Occurs in myelinated axons where action potentials "jump" between nodes of Ranvier.

    • Myelin insulates the axon, increasing conduction speed.

    • Voltage-gated Na+ channels at the nodes regenerate the action potential.

  2. Composition and features of the neuron’s cell membrane:

    • Phospholipid Bilayer: Semi-permeable barrier.

    • Membrane Proteins: Ion channels, receptors, and pumps.

    • Cholesterol: Adds rigidity.

    • Glycoproteins: Cell signaling and adhesion.

  3. What is the role of ATP?

    • Provides energy for the Na+/K+ pump, maintaining ion gradients critical for action potential generation.

    • Fuels synaptic vesicle recycling and neurotransmitter synthesis.

  4. Ionotropic vs. Metabotropic receptors:

    • Ionotropic: Fast-acting; ligand-gated ion channels (e.g., AMPA, NMDA for glutamate).

    • Metabotropic: Slow; G-protein-coupled receptors (e.g., dopamine D1/D2 receptors).

  5. Metabotropic signaling through second messengers:

    • Neurotransmitter binding activates G-proteins.

    • G-proteins stimulate effectors (e.g., adenylyl cyclase).

    • Second messengers (e.g., cAMP) mediate downstream effects like protein phosphorylation.


Synaptic Dynamics

  1. Elements in the presynaptic terminal:

    • Synaptic vesicles, docking proteins (e.g., SNAREs), mitochondria, and voltage-gated Ca²⁺ channels.

  2. Neurotransmitter removal mechanisms:

    • Reuptake: Transport back into the presynaptic cell (e.g., via SERT for serotonin).

    • Enzymatic degradation: Breakdown by enzymes (e.g., acetylcholinesterase for acetylcholine).

    • Diffusion: Passive dispersal from the synaptic cleft.

  3. Neurotransmitter regulation via negative feedback:

    • Autoreceptors: Located on the presynaptic neuron; inhibit further release or synthesis (e.g., dopamine D2 autoreceptors).


Neurotransmitters

  1. Neurotransmitter-to-Brain Region, Function, and Drug:

    • Dopamine: Basal ganglia; motor control, reward; targeted by antipsychotics, stimulants.

    • Serotonin: Raphe nuclei; mood regulation; SSRIs.

    • Glutamate: Cortex; excitatory signaling; NMDA receptor antagonists (e.g., ketamine).

    • GABA: Basal ganglia, cerebellum; inhibitory signaling; benzodiazepines.


Brain and Behavior

  1. Basal ganglia and information processing (Direct Pathway):

    • Excitation from the cortex activates the striatum.

    • Striatum inhibits the globus pallidus internus.

    • Reduced GPi activity disinhibits the thalamus, facilitating movement.

  2. Limbic system elements:

    • Amygdala, hippocampus, cingulate cortex, hypothalamus, and nucleus accumbens.


Research and Validity

  1. Animal models of disease:

    • Predictive Validity: Models predict treatment responses.

    • Face Validity: Models mimic symptoms.

    • Construct Validity: Models replicate disease mechanisms.

  2. Pharmacodynamics vs. Pharmacokinetics:

    • Pharmacodynamics: Drug effects on the body.

    • Pharmacokinetics: Drug absorption, distribution, metabolism, excretion.

  3. Agonists vs. Antagonists:

    • Agonists: Activate receptors (e.g., morphine).

    • Antagonists: Block receptor activity (e.g., naloxone).

  4. APA Ethical Principles:

    • Beneficence: Prioritize participant well-being.

    • Justice: Ensure fairness in research practices.

    • Respect: Maintain confidentiality and informed consent.


Key Disorders Overview

Schizophrenia (SZ):
  • Positive Symptoms: Delusions, hallucinations.

  • Negative Symptoms: Flat affect, catatonia.

  • Cognitive Symptoms: Disorganized thought.

Alzheimer's Disease (AD):
  • Hallmarks: ß-amyloid plaques, Tau tangles.

  • Regions: Hippocampus.

  • Treatments: Memantine, cholinesterase inhibitors.

ADHD:
  • Dopamine Dysfunction: Default Mode vs. Task-On Network imbalance.

  • Treatments: Stimulants (e.g., Adderall).

Addiction:
  • Key Mechanism: Nucleus accumbens DA elevation.

  • Treatments: Replacement strategies, sensitization.

Major Depressive Disorder:
  • HPA Dysregulation: Elevated cortisol.

  • Treatments: SSRIs, ECT, BDNF enhancement.

Anxiety Disorders:
  • Amygdala Hyperactivity.

  • Treatments: Benzodiazepines, CBT.